Keywords: biomarin, submits, eu, file, aryplase, mps, vi

BioMarin submits EU file on Aryplase for MPS VI

Article | 13 December 2004

California, USA-based BioMarin Pharmaceutical has submitted a Marketing Authorization Application to the European Medicines Agency for Aryplase (galsulfase), an investigational ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Galsulfase

Naglazyme

Go to drug listing